CN109645492A - It is a kind of with the child form composite formula and preparation method thereof for controlling allergy in advance - Google Patents
It is a kind of with the child form composite formula and preparation method thereof for controlling allergy in advance Download PDFInfo
- Publication number
- CN109645492A CN109645492A CN201910077681.4A CN201910077681A CN109645492A CN 109645492 A CN109645492 A CN 109645492A CN 201910077681 A CN201910077681 A CN 201910077681A CN 109645492 A CN109645492 A CN 109645492A
- Authority
- CN
- China
- Prior art keywords
- bag
- dosage
- lactobacillus
- antiallergic
- advance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 36
- 230000007815 allergy Effects 0.000 title claims abstract description 35
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 34
- 239000002131 composite material Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 238000009472 formulation Methods 0.000 title abstract description 4
- 239000006041 probiotic Substances 0.000 claims abstract description 54
- 235000018291 probiotics Nutrition 0.000 claims abstract description 54
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 52
- 230000003266 anti-allergic effect Effects 0.000 claims abstract description 51
- 239000000843 powder Substances 0.000 claims abstract description 50
- 230000000529 probiotic effect Effects 0.000 claims abstract description 45
- 239000000203 mixture Substances 0.000 claims abstract description 44
- 150000001875 compounds Chemical class 0.000 claims abstract description 37
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 26
- 230000000694 effects Effects 0.000 claims abstract description 26
- 229940035035 polydextrose Drugs 0.000 claims abstract description 26
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 26
- 239000001259 polydextrose Substances 0.000 claims abstract description 26
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 23
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 claims abstract description 22
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 17
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 17
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 16
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 15
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 15
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 239000000463 material Substances 0.000 claims abstract description 13
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 239000004615 ingredient Substances 0.000 claims abstract description 4
- 238000011017 operating method Methods 0.000 claims abstract description 4
- 238000002203 pretreatment Methods 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000011022 operating instruction Methods 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 12
- 241000186660 Lactobacillus Species 0.000 claims description 10
- 229940039696 lactobacillus Drugs 0.000 claims description 10
- 238000004140 cleaning Methods 0.000 claims description 9
- 238000012856 packing Methods 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 8
- 238000012946 outsourcing Methods 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 6
- 230000033228 biological regulation Effects 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000002776 aggregation Effects 0.000 claims description 3
- 238000004220 aggregation Methods 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 238000013329 compounding Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 239000005022 packaging material Substances 0.000 claims description 3
- 238000012552 review Methods 0.000 claims description 3
- 238000005070 sampling Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- 230000032258 transport Effects 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 10
- 210000000987 immune system Anatomy 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 230000002052 anaphylactic effect Effects 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000010668 atopic eczema Diseases 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 201000004624 Dermatitis Diseases 0.000 description 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000000172 allergic effect Effects 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 208000004232 Enteritis Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010022678 Intestinal infections Diseases 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000002804 anti-anaphylactic effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 238000010237 hybrid technique Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 206010049153 Allergic sinusitis Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028665 Myxoedema Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010435 allergic urticaria Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 208000003786 myxedema Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a kind of with the child form composite formula and preparation method thereof for controlling allergy in advance, composition including compound antiallergic probiotic powder and prebiotics, compound antiallergic probiotic powder includes the following raw material: lactobacillus reuteri, lactobacillus paracasei, lactobacillus acidophilus, Lactobacillus rhamnosus, prebiotics include the following raw material: polydextrose, oligofructose, DEXTROSE ANHYDROUS；The specification content of compound antiallergic antiallergic probiotic powder is at least 5,000,000,000 cfu/ bags, wherein every bag of dosage is 0.02-0.6g；Every bag of dosage of polydextrose is 0.2-1.6g, and every bag of dosage of oligofructose is 0.2-1.6g, and every bag of dosage of DEXTROSE ANHYDROUS is 0.4-0.9g；It further include following operating procedure: Step 1: the preparation of supplementary material；Step 2: material pre-treatment；Step 3: ingredient, mixing；Step 4: pack；Step 5: craft sanitary.The present invention does not have side effect by improving the immune system of anaphylactic disease patient to the beneficial bacterium of human body, can preferably solve some anaphylactogens in life because.
Description
Technical field
The present invention relates to bio-pharmaceuticals related fields, it is specially a kind of with the child form composite formula for controlling allergy in advance and
Preparation method.
Background technique
It is proved according to medical research, allergic constitution has its source in internal intestinal tract flora imbalance.Baby's nascent, exempts from
Epidemic disease systematic growth is immature, relatively easy that infection and allergy occurs, and probiotics can accelerate its maturation, make it firm
Come, thus pre- hypo-allergenic generation.Current research shows that probiotics quantity is more in baby's enteron aisle, and the probability of allergy occurs just
It is smaller.It is certain it is anaphylactoid be collapse due to gut barrier function, cause caused by a large amount of antigen challenges.It grinds
Studying carefully report probiotics has the effect of adjusting certain allergic reactions.Antianaphylactic treatment drug is mainly steroids, anti-tissue at present
Amine etc., and the effect of these drugs mainly inhibits histamine, that is, inhibits the symptom of allergy, but the simultaneously root of non-treatment allergy
Source.Also, these hormone medicines easily cause side effect, such as weight gain, osteoporosis, urination have some setbacks.And conduct
It is a kind of it is novel effect a permanent cure, and innovative treatments without side-effects, Probiotic supplement are a good alternative means.
Through market survey, wherein various anaphylactogens are the most obvious with skin disease allergy such as eczema, nettle rash etc. because in, and its
His anaphylactogen is high because of also lasting residence.There is the people of allergic constitution, always battle a lifetime with irritating symptom, ocular allergies are frequent
Cause eyes not only red but also itch, sneezing always occurs in nose allergy, nasal obstruction inhales the symptom less than air, and nettle rash, atopy
Dermatitis patient frequently results in itch all over when eating food, and has asthma defect, and a morbidity is then usually breathless, there is allergy
Property enteritis be even more normal the pain for enduring diarrhea, belly distending pain.Researches show that Lactobacillus Paracasei is secondary dry
Lactobacillus paracasei, lactobacillus reuteri can reduce the diffusion of eczema, itch and insomnia, have the baby of allergic constitution especially to mother
It is significant.And the infection of bacterium and fungi can be reduced.
We live in the environment full of pathogenic microorganisms, and immune system is important defence line for the survival of mankind,
Immune system can differentiate enemy and we, attack harmful substance, can then open one eye, wink at for harmless substance, still
Immune system is not absolute precision, can be malfunctioned sometimes yet, when immune system some harmless substances are started to carry out it is meaningless
War, human body just generates symptom on various organs just at battlefield, this is so-called anaphylactia.And Healthy People
Immune system there are two types of path -- Th1 and Th2, both paths must balanced growth, if the immunologic pathways of Th2 are too living
Jump, will allergy.In simple terms, the antianaphylactic principle of probiotics is exactly increase Th1 to generate adjusting type T cell, and inhibit
Th2.Western medicine such as antihistaminicum inhibits the function and effect of inflammatory response fast at present, preferable for the acute treatment of symptom, but due to
It can not inhibit Th2, as long as being discontinued, symptom will appear again.To reach for a long time and inhibit Th2, so that it may be adjusted through probiotics.
Lactobacillus Paracasei can be such that allergy inflammatory response transfers toward for uninflamed first type t cell immune response,
This mechanism is the inflammatory response blocking property immunological regulation of " non-antigentic specificity ", therefore Lactobacillus Paracasei can
It is effectively improved a variety of allergic symptoms caused by all types of anaphylactogens (such as dust mite, pollen etc.), including allergic asthma, anaphylaxis
Rhinitis, allergic sinusitis, allergic conjunctivitis, Atopic dermatitis, allergic urticaria, allergic eczema, anaphylaxis are inclined
Headache, hylactic pneumonia etc., but generation without any side effects.
Research is it has been found that the main pathology machine of bronchial asthma turn, is respiratory tract chronic inflammatory reaction at present, and inflammation is main
It is various inflammatory mediators such as platelet activating factor, histamine, prostaglandin, the nerve element and white three discharged by inflammatory cell
Dilute etc., these inflammatory mediators directly or indirectly injure respiratory tract epidermis or lung tissue, and respiratory tract is made to generate excess shrinkage reaction, into
One step shows myxedema, and diffusate increases, hyperemia reaction and smooth muscle spasm etc., and increases resistance of respiratory tract.No
Cross, this series of inflammatory reaction, be all dominated by second type T cell release IL-4,5,10,13 etc. because this
A little interleukins can induce B immunocyte and discharge immunoglobulin E antibodies, the hyperplasia of thermophilic Yihong white blood cell and the work of mast cell
Change and generate, and further discharges inflammatory mediator.Therefore zoopery proves, probiotics Lactobacillus Paracasei
It it is able to suppress inflammatory reaction, reduces the synthesis of immunoglobulin E, inhibit synthesis or the mast cell histamine of IL-4
Release, it will be able to inhibit anaphylactoid generation, reduce the Probability of asthma.
The parent of Typical allergic anxiety, their anxiety often from the therapeutic process of anaphylactia institute it is adjoint and
Come.Drug side-effect: worry is taken too many or leads to very much that the drowsiness, impariment of the liver is impairment of the kidney, complexion is deteriorated long；Worry that too fast medicine is hurt very much
Body, especially " steroids " " antihistaminicum "；Worry to recur after being discontinued, so that the state of an illness may become more serious, and worry
Dose must more be eaten the more, and dependence is formed.
Past can only inhibit inflammatory response in face of these above-mentioned puzzlements with antihistaminicum or steroid medicine, that is,
Allergic symptom can only be controlled by saying, taken medicine and just alleviated, and a withdrawal symptom occurs again, and nothing is only most to take medicine.In recent years, immunology
Boundary eats some pairs of beneficial bacteriums of human body by many scientific research discoveries, can improve the immune of anaphylactic disease patient
System, and the side effect as drug is not had, and above situation is hardly existed, what can also preferably be trusted comes
Solve life in some anaphylactogens because.
Summary of the invention
The purpose of the present invention is to provide a kind of with the child form composite formula and preparation method thereof for controlling allergy in advance, with
Solve the problems mentioned above in the background art.
To achieve the above object, the invention provides the following technical scheme:
It is a kind of with the child form composite formula for controlling allergy in advance, the composition including compound antiallergic probiotic powder and prebiotics,
The compound antiallergic probiotic powder includes the following raw material: lactobacillus reuteri, lactobacillus paracasei, lactobacillus acidophilus, rhamnose
Lactobacillus, the prebiotics include the following raw material: polydextrose, oligofructose, DEXTROSE ANHYDROUS；
The specification content of the compound antiallergic antiallergic probiotic powder is at least 5,000,000,000 cfu/ bags, wherein every bag of dosage is 0.02-
0.6g；
Every bag of dosage of the polydextrose is 0.2-1.6g, and every bag of dosage of the oligofructose is 0.2-1.6g, the nothing
Every bag of dosage of water glucose is 0.4-0.9g.
Preferably, the composition of the compound antiallergic probiotic powder and prebiotics mixes rear composition mixture, described
Mixture is yellowish graininess powder, every bag of content for referring to mixture, the mixing in the unit of the specification content
Every bag of content is 2g in object.
Preferably, the combination of the lactobacillus reuteri, lactobacillus paracasei, lactobacillus acidophilus, Lactobacillus rhamnosus
Ratio are as follows: 20:20:30:30.
Preferably, the polydextrose, oligofructose and DEXTROSE ANHYDROUS are by being dried.
Preferably, every bag of dosage of the compound antiallergic antiallergic probiotic powder is 0.3g, specifically, the Luo Yishi cream
Every bag of dosage of bacillus is 0.06g, and every bag of dosage of the lactobacillus paracasei is 0.06g, every bag of the lactobacillus acidophilus
Dosage is 0.09g, and every bag of dosage of the Lactobacillus rhamnosus is 0.09g.
Preferably, the dosage of the polydextrose is every bag of 0.6g.
Preferably, every bag of dosage of the oligofructose is 0.6g.
Preferably, every bag of dosage of the DEXTROSE ANHYDROUS is 0.5g.
A kind of preparation method with the child form composite formula for controlling allergy in advance, including following operating procedure:
Step 1: the preparation of supplementary material: qualified polydextrose, oligofructose, DEXTROSE ANHYDROUS will be examined to be transferred to de- parlor, taken off
Go outsourcing, will have the material of complete inner packing with water-color paintbrush be transferred to after outer bag subscript shows the name of product it is temporary between, use ultraviolet lamp
Compound antiallergic probiotic powder is transferred to de- parlor and does not have to ultraviolet light irradiation after sloughing outer packing by irradiation about 10 minutes；
Step 2: material pre-treatment: the oligofructose in formula ratio being placed in boiling drier and is dried, it is desirable that dry temperature
80 DEG C of degree, drying time 3 hours, operator must wear masks during whole operation, and hand must disinfect in alcohol, behaviour
There must not be foreign matter entrance during work；
Step 3: ingredient, mixing: accurately weighing compound probiotic powder, polydextrose, oligofructose, nothing in batches by formula rate
Water glucose is successively placed in flat mixer, carries out mixing 20min, facilitates mixture, visually inspects uniformity, wherein claims
Amount process must be through double review；
Step 4: pack: between through examining qualified said mixture to move to pack, being packed with full-automatic powder packing machine
Operation, specification are 2g/ bags, and every 20min weighing is primary, every time when weighing, it is necessary to which 10 bags of continuous sampling carry out every bag of weighing, and will
Average weight is charged to primitive operation after carrying out averagely and noted down by 10 weight claimed, checks weight differential with this, pack terminates
After weigh, calculate material balance, by the pouch installed be directly transferred to outsourcing workshop carry out product packaging；
Step 5: craft sanitary: the wearing cleaning-sterilizing that personnel pass in and out control zone is passed in and out the corresponding management of clean area by personnel
The requirement of system and operating instruction executes, and per tour terminates that post, metope, ground, instrument, equipment cleaning disinfection should be carried out；
Every batch of production terminates to clear out a gathering place according to operating instruction of clearing out a gathering place accordingly；Production container tool used must be according to phase
The clean container tool that the cleaning and sterilizing regulation answered is handled well；Personnel pass in and out general production area wearing cleaning-sterilizing and press personnel
The requirement of the corresponding management system and operating instruction that pass in and out general production area executes, per tour terminate should to carry out post, metope,
Ground, instrument, equipment cleaning disinfection；Every batch of production terminates to clear out a gathering place according to operating instruction of clearing out a gathering place accordingly.
Preferably, including following points for attention: the compound antiallergic probiotic powder should be transported before and after use at 8 DEG C or less
Defeated and storage, storage can extend the shelf-life of raw material at a temperature of lower (- 20 DEG C)；The mixture needs before processing
Risen again at room temperature to consistent with environment temperature between production operation prevents probiotics from absorbing water in auxiliary material aggregation；It is producing and processing
In the process, environment temperature should control at 25 DEG C hereinafter, humid control in 40%RH hereinafter, controlling the temperature and humidity of production environment has
Help the vital preservation of compound antiallergic probiotic powder；The water activity of entire product compounding system should control in Aw < 0.3 hereinafter,
The batching system of low moisture activity helps to maintain the stability of probiotic products；The hybrid technique of probiotic powder is used and is put step by step
Big principle carrys out mixed processing；Product packaging, which should use, blocks water, hinders oxygen and hinders the strong packaging material of vapour ability.
Compared with prior art, the beneficial effects of the present invention are:
The present invention does not have side effect by improving the immune system of anaphylactic disease patient to the beneficial bacterium of human body, can also be with
What is preferably trusted solves some anaphylactogens in life because, wherein lactobacillus reuteri has antiallergy patent strain, thoroughly
Cross intestinal mucosa, induction immunologic balance, stimulation spleen cell, reduce inflammatory reaction, can secreting bacteria usually reach inhibition and pre-
It is the effect of anti-enteric infection disease, without side-effects, safely and effectively act on.Lactobacillus paracasei is antiallergy special bacteria,
With improving eczema caused by allergy, passing through hydrolysis, TH1/TH2 immunologic balance is induced, milk protein allergy is effectively prevented
Generation effect.Lactobacillus acidophilus has the growth that can inhibit Listeria and Escherichia coli, safeguards the healthy, adjustable of enteron aisle
The balance for saving TH1/TH2, effectively extenuates the effect of the symptom of allergy.Sandlwood saccharobacillus has can be to avoid enteritis and reinforcing
Small intestine screen effect avoids the infection of pathogen, while can stablize function of intestinal canal and reduce intestines and stomach malaise symptoms, to allergy
Property eczema and Atopic dermatitis have the function of significant ground therapeutic effect.
Specific embodiment
The following is a clear and complete description of the technical scheme in the embodiments of the invention, it is clear that described embodiment
Only a part of the embodiment of the present invention, instead of all the embodiments.Based on the embodiments of the present invention, the common skill in this field
Art personnel every other embodiment obtained without making creative work belongs to the model that the present invention protects
It encloses.
Embodiment 1:
The present invention provides a kind of with the child form composite formula for controlling allergy in advance, including compound antiallergic probiotic powder and prebiotics
Composition, compound antiallergic probiotic powder includes the following raw material: lactobacillus reuteri, lactobacillus paracasei, lactobacillus acidophilus, mouse
Lee's sugar lactobacillus, prebiotics include the following raw material: polydextrose, oligofructose, DEXTROSE ANHYDROUS；
The specification content of compound antiallergic antiallergic probiotic powder is at least 5,000,000,000 cfu/ bags, wherein every bag of dosage is 0.02-0.6g；
Every bag of dosage of polydextrose is 0.2-1.6g, and every bag of dosage of oligofructose is 0.2-1.6g, DEXTROSE ANHYDROUS it is every
Bag dosage is 0.4-0.9g.
Further, the composition of compound antiallergic probiotic powder and prebiotics mixes rear composition mixture, and mixture is
Yellowish graininess powder, every bag of content for referring to mixture in the unit of specification content, every bag of content is in mixture
2g。
Further, lactobacillus reuteri, lactobacillus paracasei, acidophilus cream bar, Lactobacillus rhamnosus portfolio ratio are as follows:
20:20:30:30。
Further, polydextrose, oligofructose and DEXTROSE ANHYDROUS are by being dried.
Further, every bag of dosage of compound antiallergic antiallergic probiotic powder is 0.02g, specifically, lactobacillus reuteri
Every bag of dosage is 0.004g, and every bag of dosage of lactobacillus paracasei is 0.006g, and every bag of dosage of acidophilus cream bar is 0.006g, mouse
Every bag of dosage of Lee's sugar lactobacillus is 0.006g.
Further, the dosage of polydextrose is every bag of 0.79g.
Further, every bag of dosage of oligofructose is 0.79g.
Further, every bag of dosage of DEXTROSE ANHYDROUS is 0.4g.
Embodiment 2:
The present invention provides a kind of with the child form composite formula for controlling allergy in advance, including compound antiallergic probiotic powder and prebiotics
Composition, compound antiallergic probiotic powder includes the following raw material: lactobacillus reuteri, lactobacillus paracasei, lactobacillus acidophilus, mouse
Lee's sugar lactobacillus, prebiotics include the following raw material: polydextrose, oligofructose, DEXTROSE ANHYDROUS；
The specification content of compound antiallergic antiallergic probiotic powder is at least 5,000,000,000 cfu/ bags, wherein every bag of dosage is 0.02-0.6g；
Every bag of dosage of polydextrose is 0.2-1.6g, and every bag of dosage of oligofructose is 0.2-1.6g, DEXTROSE ANHYDROUS it is every
Bag dosage is 0.4-0.9g.
Further, the composition of compound antiallergic probiotic powder and prebiotics mixes rear composition mixture, and mixture is
Yellowish graininess powder, every bag of content for referring to mixture in the unit of specification content, every bag of content is in mixture
2g。
Further, lactobacillus reuteri, lactobacillus paracasei, lactobacillus acidophilus, Lactobacillus rhamnosus portfolio ratio
Are as follows: 20:20:30:30.
Further, polydextrose, oligofructose and DEXTROSE ANHYDROUS are by being dried.
Further, every bag of dosage of compound antiallergic antiallergic probiotic powder be 0.6g, specifically, lactobacillus reuteri it is every
Bag dosage is 0.12g, and every bag of dosage of lactobacillus paracasei is 0.12g, and every bag of dosage of lactobacillus acidophilus is 0.18g, sandlwood
Every bag of dosage of sugared lactobacillus is 0.18g.
Further, the dosage of polydextrose is every bag of 0.25g.
Further, every bag of dosage of oligofructose is 0.25g.
Further, every bag of dosage of DEXTROSE ANHYDROUS is 0.9g.
Embodiment 3:
The present invention provides a kind of with the child form composite formula for controlling allergy in advance, including compound antiallergic probiotic powder and prebiotics
Composition, compound antiallergic probiotic powder includes the following raw material: lactobacillus reuteri, lactobacillus paracasei, lactobacillus acidophilus, mouse
Lee's sugar lactobacillus, prebiotics include the following raw material: polydextrose, oligofructose, DEXTROSE ANHYDROUS；
The specification content of compound antiallergic antiallergic probiotic powder is at least 5,000,000,000 cfu/ bags, wherein every bag of dosage is 0.02-0.6g；
Every bag of dosage of polydextrose is 0.2-1.6g, and every bag of dosage of oligofructose is 0.2-1.6g, DEXTROSE ANHYDROUS it is every
Bag dosage is 0.4-0.9g.
Further, the composition of compound antiallergic probiotic powder and prebiotics mixes rear composition mixture, and mixture is
Yellowish graininess powder, every bag of content for referring to mixture in the unit of specification content, every bag of content is in mixture
2g。
Further, lactobacillus reuteri, lactobacillus paracasei, lactobacillus acidophilus, Lactobacillus rhamnosus portfolio ratio
Are as follows: 20:20:30:30.
Further, polydextrose, oligofructose and DEXTROSE ANHYDROUS are by being dried.
Further, every bag of dosage of compound antiallergic antiallergic probiotic powder be 0.3g, specifically, lactobacillus reuteri it is every
Bag dosage is 0.06g, and every bag of dosage of lactobacillus paracasei is 0.06g, and every bag of dosage of lactobacillus acidophilus is 0.09g, sandlwood
Every bag of dosage of sugared lactobacillus is 0.09g.
Further, the dosage of polydextrose is every bag of 0.6g.
Further, every bag of dosage of oligofructose is 0.6g.
Further, every bag of dosage of DEXTROSE ANHYDROUS is 0.5g.
Principle steps, including following operating procedure:
Step 1: the preparation of supplementary material: qualified polydextrose, oligofructose, DEXTROSE ANHYDROUS will be examined to be transferred to de- parlor, taken off
Go outsourcing, will have the material of complete inner packing with water-color paintbrush be transferred to after outer bag subscript shows the name of product it is temporary between, use ultraviolet lamp
Compound antiallergic probiotic powder is transferred to de- parlor and does not have to ultraviolet light irradiation after sloughing outer packing by irradiation about 10 minutes；
Step 2: material pre-treatment: the oligofructose in formula ratio being placed in boiling drier and is dried, it is desirable that dry temperature
80 DEG C of degree, drying time 3 hours, operator must wear masks during whole operation, and hand must disinfect in alcohol, behaviour
There must not be foreign matter entrance during work；
Step 3: ingredient, mixing: accurately weighing compound probiotic powder, polydextrose, oligofructose, nothing in batches by formula rate
Water glucose is successively placed in flat mixer, carries out mixing 20min, facilitates mixture, visually inspects uniformity, wherein claims
Amount process must be through double review；
Step 4: pack: between through examining qualified said mixture to move to pack, being packed with full-automatic powder packing machine
Operation, specification are 2g/ bags, and every 20min weighing is primary, every time when weighing, it is necessary to which 10 bags of continuous sampling carry out every bag of weighing, and will
Average weight is charged to primitive operation after carrying out averagely and noted down by 10 weight claimed, checks weight differential with this, pack terminates
After weigh, calculate material balance, by the pouch installed be directly transferred to outsourcing workshop carry out product packaging；
Step 5: craft sanitary: the wearing cleaning-sterilizing that personnel pass in and out control zone is passed in and out the corresponding management of clean area by personnel
The requirement of system and operating instruction executes, and per tour terminates that post, metope, ground, instrument, equipment cleaning disinfection should be carried out；
Every batch of production terminates to clear out a gathering place according to operating instruction of clearing out a gathering place accordingly；Production container tool used must be according to phase
The clean container tool that the cleaning and sterilizing regulation answered is handled well；Personnel pass in and out general production area wearing cleaning-sterilizing and press personnel
The requirement of the corresponding management system and operating instruction that pass in and out general production area executes, per tour terminate should to carry out post, metope,
Ground, instrument, equipment cleaning disinfection；Every batch of production terminates to clear out a gathering place according to operating instruction of clearing out a gathering place accordingly.
Further, for above-mentioned principle steps, including following points for attention: compound antiallergic probiotic powder is before and after use
Should be in 8 DEG C or less transports and storage, storage can extend the shelf-life of raw material at a temperature of lower (- 20 DEG C)；Mixture is adding
Risen again at room temperature to consistent with environment temperature between production operation is needed before work, prevents probiotics from absorbing water in auxiliary material aggregation；
In the process of production and processing, environment temperature should control at 25 DEG C hereinafter, humid control in 40%RH hereinafter, controlling production environment
Temperature and humidity facilitate the vital preservation of compound antiallergic probiotic powder；The water activity of entire product compounding system should be controlled in Aw
< 0.3 is hereinafter, the batching system of low moisture activity helps to maintain the stability of probiotic products；The hybrid technique of probiotic powder
Using amplification principle step by step come mixed processing；Product packaging, which should use, blocks water, hinders oxygen and hinders the strong packaging material of vapour ability.
The present invention does not have side effect by the immune system of the bacterium improvement anaphylactic disease patient beneficial to human body,
What can preferably be trusted solves some anaphylactogens in life because, wherein lactobacillus reuteri has antiallergy patent bacterium
Kind, through intestinal mucosa, induce immunologic balance, stimulation spleen cell, reduce inflammatory reaction, can secreting bacteria usually reach inhibition
And the effect, without side-effects of prevention enteric infection disease, safely and effectively act on.Lactobacillus paracasei is antiallergy special bacterium
Kind, there is eczema caused by improving allergy, by hydrolysis, induces TH1/TH2 immunologic balance, effectively prevent milk protein mistake
The effect of quick generation.Lactobacillus acidophilus, which has, can inhibit the growths of Listeria and Escherichia coli, safeguard enteron aisle health, can
The balance for adjusting TH1/TH2, effectively extenuates the effect of the symptom of allergy.Sandlwood saccharobacillus has can be to avoid enteritis and strong
Change small intestine screen effect, avoid the infection of pathogen, while function of intestinal canal can be stablized and reduce intestines and stomach malaise symptoms, to mistake
Quick property eczema and Atopic dermatitis have the function of significant ground therapeutic effect.
It although an embodiment of the present invention has been shown and described, for the ordinary skill in the art, can be with
A variety of variations, modification, replacement can be carried out to these embodiments without departing from the principles and spirit of the present invention by understanding
And modification, the scope of the present invention is defined by the appended.
Claims (10)
1. a kind of with the child form composite formula for controlling allergy in advance, which is characterized in that including compound antiallergic probiotic powder and benefit
The composition of raw member, the compound antiallergic probiotic powder includes the following raw material: lactobacillus reuteri, lactobacillus paracasei, acidophilus
Lactobacillus, Lactobacillus rhamnosus, the prebiotics include the following raw material: polydextrose, oligofructose, DEXTROSE ANHYDROUS；
The specification content of the compound antiallergic antiallergic probiotic powder is at least 5,000,000,000 cfu/ bags, wherein every bag of dosage is 0.02-
0.6g；
Every bag of dosage of the polydextrose is 0.2-1.6g, and every bag of dosage of the oligofructose is 0.2-1.6g, the nothing
Every bag of dosage of water glucose is 0.4-0.9g.
2. according to claim 1 a kind of with the child form composite formula for controlling allergy in advance, which is characterized in that described multiple
The composition for closing antiallergic probiotic powder and prebiotics mixes rear composition mixture, and the mixture is yellowish graininess powder
End, every bag of content for referring to mixture in the unit of the specification content, every bag of content is 2g in the mixture.
3. according to claim 1 a kind of with the child form composite formula for controlling allergy in advance, which is characterized in that sieve
Yi Shi lactobacillus, lactobacillus paracasei, lactobacillus acidophilus, Lactobacillus rhamnosus portfolio ratio are as follows: 20:20:30:30.
4. according to claim 1 a kind of with the child form composite formula for controlling allergy in advance, which is characterized in that described poly-
Glucose, oligofructose and DEXTROSE ANHYDROUS are by being dried.
5. according to claim 1 a kind of with the child form composite formula for controlling allergy in advance, which is characterized in that described multiple
Every bag of dosage for closing antiallergic antiallergic probiotic powder is 0.3g, and specifically, every bag of dosage of the lactobacillus reuteri is 0.06g,
Every bag of dosage of the lactobacillus paracasei is 0.06g, and every bag of dosage of the lactobacillus acidophilus is 0.09g, the rhamnose
Every bag of dosage of lactobacillus is 0.09g.
6. according to claim 1 a kind of with the child form composite formula for controlling allergy in advance, which is characterized in that described poly-
The dosage of glucose is every bag of 0.6g.
7. according to claim 1 a kind of with the child form composite formula for controlling allergy in advance, which is characterized in that described low
Every bag of dosage of Fructooligosaccharides is 0.6g.
8. according to claim 1 a kind of with the child form composite formula for controlling allergy in advance, which is characterized in that the nothing
Every bag of dosage of water glucose is 0.5g.
9. -8 any a kind of preparation method with the child form composite formula for controlling allergy in advance according to claim 1,
It is characterised in that it includes following operating procedure:
Step 1: the preparation of supplementary material: qualified polydextrose, oligofructose, DEXTROSE ANHYDROUS will be examined to be transferred to de- parlor, taken off
Go outsourcing, will have the material of complete inner packing with water-color paintbrush be transferred to after outer bag subscript shows the name of product it is temporary between, use ultraviolet lamp
Compound antiallergic probiotic powder is transferred to de- parlor and does not have to ultraviolet light irradiation after sloughing outer packing by irradiation about 10 minutes；
Step 2: material pre-treatment: the oligofructose in formula ratio being placed in boiling drier and is dried, it is desirable that dry temperature
80 DEG C of degree, drying time 3 hours, operator must wear masks during whole operation, and hand must disinfect in alcohol, behaviour
There must not be foreign matter entrance during work；
Step 3: ingredient, mixing: accurately weighing compound probiotic powder, polydextrose, oligofructose, nothing in batches by formula rate
Water glucose is successively placed in flat mixer, carries out mixing 20min, facilitates mixture, visually inspects uniformity, wherein claims
Amount process must be through double review；
Step 4: pack: between through examining qualified said mixture to move to pack, being packed with full-automatic powder packing machine
Operation, specification are 2g/ bags, and every 20min weighing is primary, every time when weighing, it is necessary to which 10 bags of continuous sampling carry out every bag of weighing, and will
Average weight is charged to primitive operation after carrying out averagely and noted down by 10 weight claimed, checks weight differential with this, pack terminates
After weigh, calculate material balance, by the pouch installed be directly transferred to outsourcing workshop carry out product packaging；
Step 5: craft sanitary: the wearing cleaning-sterilizing that personnel pass in and out control zone is passed in and out the corresponding management of clean area by personnel
The requirement of system and operating instruction executes, and per tour terminates that post, metope, ground, instrument, equipment cleaning disinfection should be carried out；
Every batch of production terminates to clear out a gathering place according to operating instruction of clearing out a gathering place accordingly；Production container tool used must be according to phase
The clean container tool that the cleaning and sterilizing regulation answered is handled well；Personnel pass in and out general production area wearing cleaning-sterilizing and press personnel
The requirement of the corresponding management system and operating instruction that pass in and out general production area executes, per tour terminate should to carry out post, metope,
Ground, instrument, equipment cleaning disinfection；Every batch of production terminates to clear out a gathering place according to operating instruction of clearing out a gathering place accordingly.
10. a kind of preparation method with the child form composite formula for controlling allergy in advance according to claim 9, feature
It is, the compound antiallergic probiotic powder should be in 8 DEG C or less transports and storage before and after use, and storage can at a temperature of -20 DEG C
To extend the shelf-life of raw material；The mixture need before processing between production operation rise again at room temperature to environment temperature
Unanimously, prevent probiotics from absorbing water in auxiliary material aggregation；In the process of production and processing, environment temperature should be controlled at 25 DEG C hereinafter, wet
Degree control is in 40%RH hereinafter, the water activity of entire product compounding system should be controlled in Aw < 0.3 hereinafter, probiotic powder mixes
Technique is closed using amplification principle step by step come mixed processing；Product packaging, which should use, blocks water, hinders oxygen and hinders the strong packaging material of vapour ability.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910077681.4A CN109645492A (en) | 2019-01-28 | 2019-01-28 | It is a kind of with the child form composite formula and preparation method thereof for controlling allergy in advance |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910077681.4A CN109645492A (en) | 2019-01-28 | 2019-01-28 | It is a kind of with the child form composite formula and preparation method thereof for controlling allergy in advance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109645492A true CN109645492A (en) | 2019-04-19 |
Family
ID=66120766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910077681.4A Pending CN109645492A (en) | 2019-01-28 | 2019-01-28 | It is a kind of with the child form composite formula and preparation method thereof for controlling allergy in advance |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109645492A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110353144A (en) * | 2019-08-14 | 2019-10-22 | 上海首源生物技术有限公司 | A kind of probiotics solid beverage and its preparation process |
| CN113974168A (en) * | 2021-09-10 | 2022-01-28 | 北京新华联协和药业有限责任公司 | Composite probiotic composition with anti-allergic effect, application and preparation |
| WO2023066328A1 (en) * | 2021-10-22 | 2023-04-27 | 青岛大学 | Use of lactobacillus reuteri from breast milk in prevention and treatment of atopic dermatitis |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104894021A (en) * | 2015-06-03 | 2015-09-09 | 宜兰食品工业股份有限公司 | Lactobacillus paracasei strain and application thereof |
| CN105146268A (en) * | 2015-08-28 | 2015-12-16 | 广东帝氏医药生物有限公司 | Herbal probiotic powder and preparation method thereof |
| CN107468716A (en) * | 2017-08-24 | 2017-12-15 | 北京亦贝安生物医药科技有限公司 | A kind of probiotics and prebiotics compound preparation and its processing method |
| CN107912589A (en) * | 2017-12-21 | 2018-04-17 | 广州莱可福生物科技有限公司 | Containing probiotics and enteron aisle and the pressed candy of immunity and preparation method thereof can be improved |
| CN108065400A (en) * | 2016-11-11 | 2018-05-25 | 湖南博佰生物科技有限公司 | One kind can antianaphylactic probiotic powder |
-
2019
- 2019-01-28 CN CN201910077681.4A patent/CN109645492A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104894021A (en) * | 2015-06-03 | 2015-09-09 | 宜兰食品工业股份有限公司 | Lactobacillus paracasei strain and application thereof |
| CN105146268A (en) * | 2015-08-28 | 2015-12-16 | 广东帝氏医药生物有限公司 | Herbal probiotic powder and preparation method thereof |
| CN108065400A (en) * | 2016-11-11 | 2018-05-25 | 湖南博佰生物科技有限公司 | One kind can antianaphylactic probiotic powder |
| CN107468716A (en) * | 2017-08-24 | 2017-12-15 | 北京亦贝安生物医药科技有限公司 | A kind of probiotics and prebiotics compound preparation and its processing method |
| CN107912589A (en) * | 2017-12-21 | 2018-04-17 | 广州莱可福生物科技有限公司 | Containing probiotics and enteron aisle and the pressed candy of immunity and preparation method thereof can be improved |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110353144A (en) * | 2019-08-14 | 2019-10-22 | 上海首源生物技术有限公司 | A kind of probiotics solid beverage and its preparation process |
| CN113974168A (en) * | 2021-09-10 | 2022-01-28 | 北京新华联协和药业有限责任公司 | Composite probiotic composition with anti-allergic effect, application and preparation |
| WO2023066328A1 (en) * | 2021-10-22 | 2023-04-27 | 青岛大学 | Use of lactobacillus reuteri from breast milk in prevention and treatment of atopic dermatitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10617728B2 (en) | Probiotics and prebiotics compound preparation and processing method thereof | |
| CN109645492A (en) | It is a kind of with the child form composite formula and preparation method thereof for controlling allergy in advance | |
| CN104415061B (en) | Edible composition and its production and use | |
| Khani et al. | Postbiotics as potential promising tools for SARS‐CoV‐2 disease adjuvant therapy | |
| CN101612159B (en) | Application of 20(S)-ginsenoside Rh2 compound in preparing anti-fatigue medicament | |
| Cornejo et al. | Systematic approach for severe respiratory failure due to novel A (H1N1) influenza | |
| Zhu et al. | Intestinal probiotics in relieving clinical symptoms of severe hand, foot, and mouth disease and potential mechanism analysis. | |
| WO2022112927A1 (en) | Methods of preventing, delaying or ameliorating atopic diseases | |
| Patel et al. | Immunomodulatory effects of probiotics in the treatment of human immunodeficiency virus (HIV) infection | |
| US20230158089A1 (en) | Probiotic compositions and methods of use | |
| CN105726491A (en) | Polyhexamethylene guanidine medicine for treating stomach disease and preparation method and application thereof | |
| Meirlaen et al. | Probiotics in the prevention and management of allergic diseases (asthma and allergic rhinitis) | |
| CN105194658A (en) | Traditional Chinese medicinal preparation for treating obesity and enhancing physique and preparation method of traditional Chinese medicinal preparation | |
| RU2176668C1 (en) | Strain of bacterium lactobacillus acidophilus nv ep 317/402 "narine" tnci used for preparing curative-prophylactic preparations for intestine microflora normalization | |
| Archer et al. | Milmed treatment alleviated or abolished allergy | |
| Diwan et al. | Bank on Microbiome to keep the Body Healthy | |
| CN109432085A (en) | Application of the eurycomanone in preparation prevention and treatment male's Delayed onset hypogonadism drug, food and health care product | |
| CN115251339B (en) | Functional food composition for increasing bone mineral density by regulating intestinal flora and preparation method thereof | |
| EP4368252A2 (en) | Mixture of probiotic bacteria strains for use in the treatment of allergic asthma and with recurrent wheezing, preferably in paediatric subjects | |
| Slominski | COVID-19 cytokine storms perhaps better stopped by the CYP11A1 Vitamin D pathway–Aug 11, 2020 | |
| Tyagi et al. | Probiotics for Improving COVID-19 Infection-Linked Microbiome Disparities in Gut | |
| Ciprandi et al. | The PRObiotics in Pediatric Asthma Management (PROPAM) study: a post-hoc analysis in schoolchildren. | |
| CN106215080A (en) | A kind of pharmaceutical composition for the treatment of bronchial asthma of child containing Procaterol Hydrochloride and preparation method thereof | |
| CN105853667A (en) | Probiotics fermentation Liuwei Dihuang composition as well as preparation method and application thereof | |
| Sultana | ARE PROBIOTICS HELPFUL FOR ALLERGIES? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190419 |